信邦制药(002390) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥1,542,651,968.87, representing a decrease of 5.06% compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥109,532,373.37, an increase of 90.66% year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥79,405,077.92, down 1.78% from the previous year[6]. - Total operating revenue for the third quarter was ¥4,686,217,833.13, a decrease of 0.78% compared to ¥4,723,072,877.26 in the previous year[26]. - Net profit for the period reached ¥276,722,271.76, an increase of 14.09% from ¥242,580,888.16 in the same quarter last year[29]. - The total comprehensive income attributable to the parent company was CNY 241,031,448.38, an increase from CNY 210,077,765.52 in the previous period, representing a growth of approximately 14.74%[31]. Assets and Liabilities - The total assets at the end of the reporting period were ¥9,955,003,084.45, reflecting a growth of 3.39% compared to the end of the previous year[6]. - Current liabilities totaled ¥2,896,623,285.62, up from ¥2,754,617,403.73, indicating a rise of 5.15%[25]. - The total liabilities of the company reached ¥2,937,685,628.90, an increase from ¥2,800,143,777.11, reflecting a growth of 4.91%[25]. - The company's equity attributable to shareholders increased to ¥6,771,907,040.51 from ¥6,619,762,004.21, showing a growth of 2.30%[25]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥532,062,786.18, an increase of 85.77% compared to the same period last year[11]. - The net cash flow from financing activities was ¥186,244,247.19, a significant increase of 131.61% compared to the same period last year[11]. - The total cash inflow from financing activities was CNY 1,627,019,026.65, down from CNY 3,397,276,080.07 in the previous period, reflecting a decrease of approximately 52.00%[35]. - The net cash flow from investing activities was -CNY 77,355,165.38, an improvement from -CNY 612,894,551.03 in the previous period, showing a reduction in cash outflow[35]. - The company reported a net increase in cash and cash equivalents of CNY 640,950,847.79, compared to a net decrease of CNY 915,757,091.01 in the previous period[35]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 75,592[14]. - The largest shareholder, Guizhou Jinyu Industrial Investment Partnership, holds 17.76% of shares, totaling 360,000,000 shares[14]. - The second largest shareholder, Harbin Yuxi Venture Capital, holds 17.70% of shares, totaling 358,764,349 shares[14]. - The company has a total of 83,376,743 shares held in a repurchase special account, representing 4.11% of total shares[18]. - The company has a significant portion of shares pledged, with 358,764,349 shares from Harbin Yuxi Venture Capital being pledged[14]. - The company is controlled by Guizhou Jinyu Industrial Investment Partnership and individuals An Huai Liao and An Ji, who are acting in concert[18]. Research and Development - The company reported a decrease in R&D expenses to ¥450,762.86, down 39.56% compared to the previous year due to the sale of a subsidiary[11]. - Research and development expenses for the quarter were ¥450,762.86, significantly lower than ¥745,793.00 in the previous year, indicating a reduction of 39.66%[26]. Earnings and Expenses - The basic earnings per share for Q3 2022 was ¥0.0563, up 90.20% year-on-year[6]. - Financial expenses decreased to ¥40,736,502.38 from ¥82,646,490.85, a reduction of 50.74%[29]. - Investment income surged to ¥37,426,822.02, a remarkable increase of 1043.54% year-on-year[11]. - Investment income rose to ¥37,426,822.02, compared to ¥3,272,898.11 in the previous year, marking a substantial increase[29].